Oncotype DX Genomic Prostate Score

Oncotype DX Genomic Prostate Score The Oncotype DX Genomic Prostate Score (GPS) assay is the only genomic assay designed for men with clinically low-risk or favorable intermediate-risk cancer to help make treatment decisions at the time of diagnosis. The assay analyzes prostate cancer gene activity to predict disease aggressiveness.

It examines interactions among genes in the tumor to better understand the unique biology of the cancer—a science known as genomics—for prostate cancer patients. Essentially, the Oncotype DX GPS assay provides more specific and individualized information about prostate cancer aggressiveness based on the biology of the tumor. The assay:

The Oncotype DX GPS assay is for men who have:

Leverage adverse pathology to assess tumor aggressiveness and inform immediate treatment decisions1,2

Adverse pathology is the presence of high-grade (Gleason Score >4 + 3) and/or non-organ-confined disease (pT3+). It provides an immediate snapshot of the risk of aggressive disease at the time of biopsy.

Biopsy alone often misses patients with high risk of adverse pathology.

LOW risk of adverse pathology

These patients have lower risk of disease progression and should consideractive surveillance

HIGH risk of adverse pathology

These patients have higher risk of disease progression and should consider immediate treatment

Predicts BOTH clinical risk and tumor aggressiveness

The Oncotype DX Genomic Prostate Score test provides a comprehensive risk profile for personalized information to guide treatment decisions.

Oncotype DX GPS assay is proven to be an independent predictor of:

Clinical risk:

• Tumor aggressiveness:

Multiple biologic pathways were more predictive than any single pathway alone2

Measured genes:

ANDROGEN SIGNALING

AZGP1
FAM13C
KLK2
SRD5A2

CELLULAR ORGANIZATION

FLNC
GSN
GSTM2
TPM2

STROMAL RESPONSE

BGN
COL1A1
SFRP4

CELLULAR PROLIFERATION

TPX2

REFERENCE

ARF1
ATP5E
CLTC
GPS1
PGK1

The GPS assay was:

Included within NCCN guidelines

NCCN Guidelines include the GPS assay as a Category 2A molecular testing option for consideration in prostate cancer patients with clinically low-risk and favorable intermediate-risk disease (life expectancy >10 years).

Clear advantages for your patients

The Oncotype DX GPS assay has been developed and studied in over 4,500 patients.3 The results from the assay refine risk assessment, help guide treatment decisions, and potentially impact patient quality of life.

Contact us

For more information about the test contact us.

References

  1. Klein et al. Eur Urol. 2014.
  2. Cullen et al. Eur Urol. 2014.
  3. Van Den Eeden et al. Eur Urol. 2018.
  4. Kozminski et al. Eur Oncol. 2016.
  5. Eggener et al. J Urol. 2011.
  6. Knezevic et l. SUO. 2013.
  7. Data on file. Genomic Health, Inc.
  8. Badani et al. Urol Pract. 2015.
  9. Dall’Era et al. Urol Pract. 2015.

* Kaiser Permanente Northern California (KPNC) retrospective cohort study N=279 clinically low-, intermediate-, and high-risk patients; biopsy. This study estimated 10-year mortality and metastasis risk based on patients after radical prostatectomy. †University of California, San Francisco (UCSF) prospective validation study: N=395 clinically low-risk patients; needle biopsy.